BMJ (Clinical research ed.) · 2008
Does a functional activity programme improve function, quality of life, and falls for residents in long term care? Cluster randomised controlled trial.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kerse Ngaire, Peri Kathy, Robinson Elizabeth, Wilkinson Tim, von Randow Martin, Kiata Liz, Parsons John, Latham Nancy, Parsons Matthew, Willingale Jane, Brown Paul, Arroll Bruce
Аннотация
OBJECTIVE: To assess the effectiveness of an activity programme in improving function, quality of life, and falls in older people in residential care.
DESIGN: Cluster randomised controlled trial with one year follow-up.
SETTING: 41 low level dependency residential care homes in New Zealand.
PARTICIPANTS: 682 people aged 65 years or over.
INTERVENTIONS: 330 residents were offered a goal setting and individualised activities of daily living activity programme by a gerontology nurse, reinforced by usual healthcare assistants; 352 residents received social visits.
MAIN OUTCOME MEASURES: Function (late life function and disability instruments, elderly mobility scale, FICSIT-4 balance test, timed up and go test), quality of life (life satisfaction index, EuroQol), and falls (time to fall over 12 months). Secondary outcomes were depressive symptoms and hospital admissions.
RESULTS: 473 (70%) participants completed the trial. The programme had no impact overall. However, in contrast to residents with impaired cognition (no differences between intervention and control group), those with normal cognition in the intervention group may have maintained overall function (late life function and disability instrument total function, P=0.024) and lower limb function (late life function and disability instrument basic lower extremity, P=0.015). In residents with cognitive impairment, the likelihood of depression increased in the intervention group. No other outcomes differed between groups.
CONCLUSION: A programme of functional rehabilitation had minimal impact for elderly people in residential care with normal cognition but was not beneficial for those with poor cognition. Trial registration Australian Clinical Trials Register ACTRN12605000667617.
DESIGN: Cluster randomised controlled trial with one year follow-up.
SETTING: 41 low level dependency residential care homes in New Zealand.
PARTICIPANTS: 682 people aged 65 years or over.
INTERVENTIONS: 330 residents were offered a goal setting and individualised activities of daily living activity programme by a gerontology nurse, reinforced by usual healthcare assistants; 352 residents received social visits.
MAIN OUTCOME MEASURES: Function (late life function and disability instruments, elderly mobility scale, FICSIT-4 balance test, timed up and go test), quality of life (life satisfaction index, EuroQol), and falls (time to fall over 12 months). Secondary outcomes were depressive symptoms and hospital admissions.
RESULTS: 473 (70%) participants completed the trial. The programme had no impact overall. However, in contrast to residents with impaired cognition (no differences between intervention and control group), those with normal cognition in the intervention group may have maintained overall function (late life function and disability instrument total function, P=0.024) and lower limb function (late life function and disability instrument basic lower extremity, P=0.015). In residents with cognitive impairment, the likelihood of depression increased in the intervention group. No other outcomes differed between groups.
CONCLUSION: A programme of functional rehabilitation had minimal impact for elderly people in residential care with normal cognition but was not beneficial for those with poor cognition. Trial registration Australian Clinical Trials Register ACTRN12605000667617.